---
title: "Eisai and CORE Biomedicine agree on global licence for oncology pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294186150.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-29T07:50:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294186150.md)
  - [en](https://longbridge.com/en/news/294186150.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294186150.md)
generator: "portal-rs"
---

# Eisai and CORE Biomedicine agree on global licence for oncology pipeline

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [4523.JP](https://longbridge.com/en/quote/4523.JP.md)

## Related News & Research

- [01:21 ETCanada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®](https://longbridge.com/en/news/297600003.md)
- [BioArctic says China approves Leqembi subcutaneous autoinjector for initiation treatment](https://longbridge.com/en/news/297858424.md)
- [LEQEMBI IQLIK(R) (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease](https://longbridge.com/en/news/297222768.md)
- [08:02 ETRADIATION BUSINESS SOLUTIONS ENCOURAGES INDUSTRY-WIDE FEEDBACK ON PROPOSED MEDICARE PAYMENT CHANGES](https://longbridge.com/en/news/298035153.md)
- [How Investors May Respond To Eisai (TSE:4523) Advancing Lecanemab Data And New CNS Oncology Filings](https://longbridge.com/en/news/292407767.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**